Emmaus Life Sciences, Inc. (EMMA)

Market Cap	2.59M
Revenue (ttm)	20.43M
Net Income (ttm)	-3.50M
Shares Out	63.87M
EPS (ttm)	-0.06
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	4,479
Average Volume	40,302
Open	0.0470
Previous Close	0.0405
Day's Range	0.0360 - 0.0470
52-Week Range	0.0001 - 0.1300
Beta	6.73
RSI	63.70
Earnings Date	Mar 31, 2025

About Emmaus Life Sciences

Emmaus Life Sciences, Inc., a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company’s lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older. Its pipeline products include ELS001/ELS007, a pharmaceutical grade L-glutamine, which has completed phase 3 clinical trial to treat sickle cell ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2000
• Employees: 55
• Stock Exchange: OTCMKTS
• Ticker Symbol: EMMA

Financial Performance

In 2023, Emmaus Life Sciences's revenue was $29.60 million, an increase of 60.94% compared to the previous year's $18.39 million. Losses were -$3.73 million, -64.87% less than in 2022.